Point-of-care testing for infectious diseases In a recent Q&A interview with Clearstate’s global… In-vitro diagnostics | Point-of-care testing (POCT) | Global | IVD Gateway | Point-of-care testing (POCT)
Are there concerns with the supply chain for point-of-care testing reagents and controls in some parts of the world? In a recent Q&A interview, Clearstate’s global managing… In-vitro diagnostics | Point-of-care testing (POCT) | Global | Point-of-care testing (POCT)
What technology will revolutionise the point-of-care testing market? In a recent Q&A interview, Clearstate’s global managing… In-vitro diagnostics | Point-of-care testing (POCT) | Global | Point-of-care testing (POCT)
How Indonesia’s healthcare transformation will impact its IVD market Indonesia’s in-vitro diagnostics (IVD) market will recover… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Middle East IVD market to recover to pre-pandemic growth rates from 2024 The Middle East IVD market has mostly recovered to… Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Cardiac biomarker testing market outlook in Latin America The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Americas | IVD Gateway | Point-of-care testing (POCT)
The future of point-of-care cardiac biomarker testing With longer life expectancies in APAC, there is an… In-vitro diagnostics | Point-of-care testing (POCT) | Global | IVD Gateway | Point-of-care testing (POCT) | The Gateway
Cardiac biomarker testing market outlook in Asia-Pacific The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Asia | IVD Gateway | Point-of-care testing (POCT)
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT) | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
Point-of-care vs. lab-based covid-19 testing Covid-19 testing has emerged as a top priority for clinical… In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)